Zinger Key Points
- Teladoc reported second-quarter revenue of $642.4 million, down 2% year-over-year.
- The company withdrew full year guidance.
- Discover Fast-Growing Stocks Every Month
Telehealth company Teladoc Health Inc TDOC reported second-quarter financial results after market close Wednesday.
Here are the key highlights.
What Happened: Teladoc reported second-quarter revenue of $642.4 million, down 2% year-over-year. The revenue total missed a Street consensus estimate of $649.7 million, according to data from Benzinga Pro.
The company reported a loss of 28 cents per share in the second quarter, beating a Street estimate of a loss of 35 cents per share.
Integrated Care segment revenue of $377.4 million was up 5% year-over-year in the quarter, with BetterHealth segment revenue of $265.0 million down 9% year-over-year in the quarter.
U.S. revenue was $540.8 million in the second quarter, down 4% year-over-year. International revenue was $101.6 million in the second quarter, up 12% year-over-year.
"I am excited to have joined Teladoc Health and for the opportunity to lead the company going forward, building on our strengths while driving higher levels of performance. Our scaled position, core capabilities, and talented employees position us well in this regard," Teladoc Health CEO Chuck Divita said.
Read Also: 13 Analysts Assess Teladoc Health: What You Need To Know
What's Next: The company said it is withdrawing its full year financial outlook for its consolidated operations and the BetterHealth segment. A three-year outlook for consolidated operations is also being withdrawn by the company.
"While we achieved solid performance in the Integrated Care segment, continued headwinds in the BetterHealth segment impacted overall results," Divita said. "We are focused on addressing the work ahead of us with urgency to unlock greater value across the company over time."
TDOC Price Action: Teladoc shares are down 13% to $8.19 in after-hours trading Wednesday, versus a 52-week trading range of $8.73 to $30.15.
Read Next:
Photo: Ground Picture/Shutterstock.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.